The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 20 December 2005, www.theannals.com, DOI 10.1345/aph.1G143.
 The Annals of Pharmacotherapy: Vol. 40, No. 1, pp. 124-127. DOI 10.1345/aph.1G143
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nair, K. V
Right arrow Articles by Saseen, J. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nair, K. V
Right arrow Articles by Saseen, J. J

Quality Assessment of Dyslipidemia in Managed Care: Current Best Evidence Should Be Used to Benchmark Quality

Kavita V Nair, PhD

Assistant Professor, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, CO

Joseph J Saseen, PharmD FCCP BCPS

Associate Professor, School of Pharmacy, University of Colorado at Denver and Health Sciences Center

Reprints: Dr. Nair, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, 4200 E. Ninth Ave., Box C-238, Denver, CO 80262-0001, fax 303/315-4630, Kavita.Nair{at}uchsc.edu

Quality measurements in managed care allow purchasers of health care to distinguish between health plans. Existing measures (Health Plan Employer Data and Information Set goals) for treatment of dyslipidemia provide a limited snapshot about quality of care for members within commercial health plans. Newer evidence (ie, the Heart Protection Study) and consensus guidelines (the National Cholesterol Education Program) expand the definition of high-risk populations and emphasize pharmacotherapy in managing dyslipidemia. We believe that newer evidence and standards provide health plans with the best opportunity to accurately assess the quality of dyslipidemia care for their populations. We propose a broad framework that provides health plans with guidance on developing a new quality measure for dyslipidemia that focuses on pharmacotherapy.

Key Words: dyslipidemia, managed care, performance measure

Published Online, December 20, 2005. www.theannals.com, DOI 10.1345/aph.1G143




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.